akampion News

Please click here to subscribe to regular news updates from the akampioneer.com
Thursday, July 21, 2016

Company News: New CELL Study presents groundbreaking pre-clinical work: developing immune therapy to potentially treat serious influenza A

- MEDI8852 blocked all influenza A with unique binding properties

A paper published today by Cell presents pre-clinical work to develop a promising new antibody, MEDI8852, as a potential therapy to treat influenza caused by numerous type A strains – the source of seasonal and pandemic outbreaks. The findings also highlight the mechanisms of action of MEDI8852, which along with its unique binding properties, point to valuable implications for the design of a universal influenza vaccine that can address the unpredictable nature of the flu virus.

“The results of this study confirm how MEDI8852’s unique molecular features have the potential to differentiate it from current treatment options for influenza, with the potential to become an important anti-influenza candidate during pandemic periods,” said JoAnn Suzich, Vice President, R&D, MedImmune.

Thursday, July 21, 2016

Company News: Molecular Health Strengthens U.S. Based Executive Management Team

 

- Appoints Gerry Sheridan as Chief Financial Officer

- Appoints Dr. Les Paul as Chief Medical Officer

Molecular Health, a leader in precision medicine technology focused on commercializing products utilizing its proprietary Dataome™ technology platform, today announced it has strengthened its leadership team with the appointment of two U.S.-based executives. Gerry Sheridan will serve as Chief Financial Officer and Dr. Les Paul as Chief Medical Officer. Mr. Sheridan and Dr. Paul will be based in the Company’s U.S. headquarters in Boston to facilitate the Company’s expansion into the U.S. commercial markets and building of an expanded U.S. operational infrastructure.